UMMC Navigation

Available Trials

Neurological and Brain Cancers

For more information regarding these studies, contact Cancer Research and Registry at (601) 984-1095

Glioblastoma/Gliosarcoma

A071102: Testing Temozolomide with Veliparib Or Placebo In Specific Patients with Newly Diagnosed Glioblastoma Multiforme

This study is for patients who have a type of brain tumor called a glioblastoma multiforme (GBM) and that have completed the first part of treatment with radiation combined with the chemotherapy drug temozolomide (TMZ).

The purpose of this study is to compare the effects, good or bad, of the usual treatment (temozolomide) with or without the addition of the investigational drug veliparib for people whose brain tumors show a change in a small region of DNA (gene) called O6-methylguanine methyltransferase (MGMT). The use of TMZ is the standard of care. The combination of veliparib with TMZ is experimental. Veliparib is an investigational drug that has not been approved by the FDA for any indication.

Principal Investigator: Mark Anderson, MD

A071401:Phase II Trial Of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

The purpose of this study is to test good and bad effects of these two different drugs against meningioma tumors with altered genes. Today, therapy for meningioma is the same for all patients, and is not based on tumor genetic testing. This trial is trying to see if tumor genetic testing would be helpful at guiding treatment in patients such as you. Researchers have looked at the DNA material (genes) that can be affected in meningioma and have found several genes that are altered, or mutated. These include the genes called SMO and NF2. When the SMO or NF2 genes are altered, it can cause a tumor to grow. There are medications that target these 2 genes.

The medication, vismodegib, blocks the SMO receptor. Vismodegib has already been FDA-approved to treat basal cell cancer, which is a type of skin cancer. The medication, GSK2256098, blocks FAK, and seems to work better in tumors that have NF2-mutations. GSK2256098 has been tested in other cancers.

Principal Investigator: Barbara Craft, MD